US fetal monitoring market boom expected:
This article was originally published in Clinica
US sales of stand-alone fetal monitoring systems and disposable sensors are expected to rise to $69.8 million by 2003, a threefold increase from this year's projected sales of $16.7 million. The introduction of two new technologies - fetal pulse oximetry, which will be used in intrapartum foetal monitors and non-invasive bilirubin screening - will also contribute to the expansion of the $249 million US neonatal/perinatal products market. Non-invasive bilirubin screening is expected to create a $16.3 million US market in the first year of launch (2000) and increase in value to $34.9 million by 2003, reports MedPro Monthly.
You may also be interested in...
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.